Catalent Inc (NYSE:CTLT)
| 76.03 Delayed Data As of Sep 23 |  -3.03 / -3.83%Today’s Change | 74.74 Today|||52-Week Range 142.09 | -40.62% Year-to-Date |
Latest CTLT News | Press Releases
| 3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio Sep 19 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 79.06 |
| Today’s open | 78.12 |
| Day’s range | 74.75 - 78.31 |
| Volume | 2,406,883 |
| Average volume (3 months) | 1,155,702 |
| Market cap | $13.7B |
Data as of 4:00pm ET, 09/23/2022
Growth & Valuation
| Earnings growth (last year) | -9.24% |
| Earnings growth (this year) | -1.24% |
| Earnings growth (next 5 years) | +12.00% |
| Revenue growth (last year) | +20.76% |
| P/E ratio | 26.8 |
| Price/Sales | 3.96 |
| Price/Book | 2.84 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | +0.36 | +0.57% |
| INCYIncyte Corp | -0.49 | -0.73% |
| ---- | ||
| BHVNBiohaven Pharmaceuti... | +0.59 | +0.39% |
Data as of 4:00pm ET, 09/23/2022
Financials
| Next reporting date | November 8, 2022 |
| EPS forecast (this quarter) | $0.61 |
| Annual revenue (last year) | $4.8B |
| Annual profit (last year) | $503.0M |
| Net profit margin | 10.42% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Somerset, New Jersey |
Forecasts
